Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.
Qingshan You,Rong Wu,M. Ye,Peiguo Wang,Desheng Hu,Xiaodong Zhu,Jian-ji Pan,Qin Lin,J. Wang,Jianhua Wang,Chao-su Hu,Benhua Xu,Chunmei Bai,Xiaozhong Chen,Junfang Hao,Gang Wu,Yan Sun,Jin Yi Lang,Xia Li,Liying Gao
DOI: https://doi.org/10.1200/jco.2022.40.16_suppl.6001
IF: 45.3
2022-06-01
Journal of Clinical Oncology
Abstract:6001
Background:
Epidermal growth factor receptor (EGFR) is highly expressed in most NPC, and it is also an essential factor of prognosis for NPC. nimotuzumab is a humanized anti-EGFR monoclonal antibody. Retrospective clinical studies showed that nimotuzumab combined with chemo-radiotherapy had better survival benefits in locally advanced NPC. The present study is a confirmatory study that aims to assess the clinical efficacy of long-term survival and safety of nimotuzumab combined with chemo-radiotherapy in locally advanced NPC patients.
Methods:
Patients with locally advanced NPC were randomized (3:1) to receive nimotuzumab (200 mg, weekly, 7-8 weeks) plus chemo-radiotherapy (Arm A) versus chemo-radiotherapy (intensity-modulated radiation therapy or conventional radiotherapy, cisplatin100mg/m
2
/d, 21days/cycle, three cycles) plus placebo (Arm B) as front-line therapy. The primary endpoint was a 5-year OS rate, and the secondary endpoints included disease-free survival and safety.
Results:
482 patients in 24 study sites were enrolled (361 in Arm A vs. 121 in Arm B). Both groups were well balanced regarding age, gender, race and ethnicity. The 5-year OS rate was 76.9% in Arm A compared to 64.3% in Arm B (log-rank=4.125, p=0.042). The median DFS was 50.6 months and 42.6 months in Arm A and B, respectively. The 5-year DFS rate was 40.0% in Arm A compared to 14.4% in Arm B (log-rank=1.701, p=0.192). The combination of nimotuzumab plus chemo-radiotherapy was well tolerated. The incidence of adverse drug reactions (ADRs) in Arm A was similar to Arm B (35.7% vs. 42.1%, p=0.207), and the grade 3-5 ADRs as well (17.7% vs.15.7%, p=0.609).
Conclusions:
Nimotuzumab plus chemo-radiotherapy increase 5-year OS of NPC patients with good safety profile.
Clinical trial information: 01074021.
Medicine